the acute coronary syndrome due to the left main coronary artery (lmca) thrombosis is a clinically rare and catastrophic event.   we describe a young man ( smoker, alcoholic, and drug abuser) with a history of recent surgery and typical chest pain who had non-occlusive lmca thrombosis in coronary angiography. the thrombosis was successfully treated with two 180 µ/kg intracoronary boluses of ept...

Background—The relative anti-aggregatory effects of currently prescribed platelet glycoprotein IIb/IIIa receptor antagonists during and after percutaneous coronary intervention for acute coronary syndromes have not been established. Methods and Results—We randomized 70 acute coronary syndrome patients undergoing percutaneous coronary intervention to receive abciximab, eptifibatide, or tirofiban...

BACKGROUND Only limited data describe relationships between stent parameters (length and diameter), adverse events after percutaneous coronary intervention, and effects of platelet glycoprotein IIb/IIIa blockade by stent parameters. METHODS AND RESULTS In this post hoc analysis of the 1983 patients receiving a stent in the Enhanced Suppression of the Platelet Glycoprotein IIb/IIIa Receptor wi...

Background- A reactivation of ischemia after the discontinuation of intravenous heparin in acute coronary syndromes has been described. The effect of glycoprotein IIb/IIIa blockade on heparin rebound is unknown. Methods and Results- Patients with acute coronary syndromes who received heparin therapy but not initial revascularization in the Platelet IIb/IIIa in Unstable angina: Receptor Suppress...

hese failed procedures, an additional analysis was stated a priori in etail in the statistical analysis plan prior to unblinding in which he lowest (i.e., worst) CFR from the prior ESPRIT (Enhanced uppression of the Platelet IIb/IIIa Receptor with Integrilin herapy) substudy (0.55) was imputed to those patients with a ailed procedure. When patients with a failed procedure were ncluded in the an...

Abstract Background Glycoprotein IIb/IIIa inhibitor use in acute ischemic stroke (AIS) during mechanical thrombectomy (MT) and stenting angioplasty is a topic consistently debated due to concerns over safety efficacy. Tirofiban glycoprotein used throughout the world now more commonly MT. We report analysis of all AIS patients treated with Eptifibatide + MT vs. Tirofiban + MT. Methods Using pros...

Acute thrombocytopenia is a recognized complication of treatment with GPIIb/IIIa inhibitors whose cause is not yet known. We studied 9 patients who developed severe thrombocytopenia (platelets less than 25 x 10(9)/L) within several hours of treatment with the GPIIb/IIIa inhibitors tirofiban (4 patients) and eptifibatide (5 patients). In each patient, acute-phase serum contained a high titer (ra...

BACKGROUND Patients with prior CABG with a subsequent non-ST-segment elevation acute coronary syndrome (ACS) pose an increasingly important clinical problem. Although GP IIb/IIIa inhibitors have improved the outcome of patients with ACS, their efficacy in patients with prior CABG has not been previously evaluated. Methods and Results- We analyzed the 30- and 180-day outcomes of patients with pr...

Whereas bleeding is the most frequent adverse event encountered in patients receiving glycoprotein (GP) IIb/IIIa inhibitors, there are currently no recommendations for how to treat such patients. The present study tested the hypothesis that infusion of desmopressin (DDAVP) reverses the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors (+l-aspirin). Study group 1 (10 healthy volunte...